News

Zeto obtains FDA 510(k) clearance for its groundbreaking next-generation EEG brain monitoring product, ONE.

SANTA CLARA, Calif., June 4, 2024 /PRNewswire/ — Zeto, Inc ., a privately owned medical technology company, has announced that its innovative next-generation product, named the ONE, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA).

Zeto ONE is approved for EEG Brain Monitoring across hospital, home, ambulance, and air transport environments.

Electroencephalography (EEG) needs in health care remain significantly unmet due to permanent shortage of trained EEG technologists. New EEG products need to be easy to use for any staff, comfortable to the patient and provide excellent signal quality. However, hospitals also require comprehensive full-montage^1,2 EEG for thorough coverage of clinically significant events, video capabilities to aid physicians in interpretation, and dependable diagnostic software for neurological emergencies. Without these elements, genuine progress in neurological care will remain unrealized.

ONE consists of a user-friendly headset equipped with 21 soft-tip electrodes positioned according to the commonly followed 10-20 EEG³system, accompanied by intuitive LED feedback for easy adjustments. It requires minimal training for any healthcare professional to operate effectively. The portable recording device captures patient video and audio, offering display and recording controls, as well as live, AI-enabled notifications for seizure activity⁴, crucial in critical or emergency scenarios^5,6. ONE seamlessly streams data to the Zeto Cloud, enabling live remote interpretations by board-certified neurologists. In addition to its role as a point-of-care system, it serves as a comprehensive EEG platform, enabling various tasks such as workflow management, patient scheduling, and report generation.

Susan Herman, M.D., Professor and Vice Chair of Clinical Affairs, Department of Neurology at Barrow Neurological Institute said, “Zeto ONE is a breakthrough EEG system, revolutionizing many aspects of emergency EEG acquisition. We know that up to 40% of brain injured emergency department and intensive care patients may experience seizures, which are often subclinical and require EEG for diagnosis. ONE fills a gap for hospitals that lack EEG resources – provides streamlined point-of care application of full 10-20 electrodes, video and audio recording, AI triage tools, and efficient connectivity to the interpreting neurologist. This enhanced workflow ensures that EEGs have high technical quality and accurate interpretations in our most critically ill patients.”

Zeto’s Founder and CEO, Aswin Gunasekar stated, “Breakthrough changes arise from the cumulative effect of years of gradual improvements. ONE is a culmination of 8+ years of customer centric product development by our industrious team. As our first-generation Wrap (WR19) headset sees increasing adoption for short-term EEGs, ONE strengthens our portfolio by democratizing access to continuous EEG brain monitoring and diagnostics. We anticipate ONE to notably advance EEG monitoring in critical care, outpatient and home settings.”

Christina Patterson, MD, Associate Professor of Pediatrics and the Director of the Epilepsy Center at UPMC Children’s Hospital of Pittsburgh said, “Zeto ONE will be a profound help to our pediatric patients by increasing access to much needed diagnostic and therapeutic interventions, particularly in Emergency Departments and Intensive Care Units where rapid application and complete EEG can make all the difference in getting a critically ill child the care they need.”

“Many hospitals in the world have no ability to obtain EEGs.,” said Robert S. Fisher, M.D., Ph.D., Director of the Stanford Epilepsy Center and former President of the American Epilepsy Society. “Zeto ONE will make it possible for them to do so. For hospitals and offices with EEG capabilities, ONE will make obtaining the EEG more efficient for the medical personnel and more comfortable for the patients.”

Zeto ONE is now available for sale. For inquiries, please call: +1 (866) 527-5549, +1 (833) ZETO EEG or email: sales@zetoinc.com

References:

Herman, S.T., et al. (2015). “J Clin Neurophysiol,” 32(2):87-95.
Kolls, B.J., and Husain, A.M. (2007). “Epilepsia,” 48(5):959-65.
Klem, G.H., Lüders, H.O., et al. (1999). “Guidelines of the International Federation of Clinical Physiology,” EEG Suppl. 52.
Enabled by Encevis. Rommens, N., et al. (2018). “Improving staff response to seizures on the epilepsy monitoring unit with online EEG seizure detection algorithms,” Epilepsy & Behavior, July 2018.
Hillman, J., et al. (2013). “National Library of Medicine,” 6(6).
Madžar, D., et al. (2016). “J Neurol,” 263:485-491.

About Zeto, Inc.

Zeto, Inc., an award-winning medical technology firm, is at the forefront of advancing EEG brain monitoring and diagnostics for healthcare. Offering wearable devices, Zeto makes brain monitoring accessible across various clinical settings including the ICU, ED, hospital, office, and home. Supported by a feature-rich cloud-based platform, Zeto provides nationwide monitoring and interpretation services rendered by neurologists, alongside AI-enabled notifications for conditions such as seizures and epilepsy. Zeto plans to expand its capabilities in the future to recognize and manage conditions such as depression and traumatic brain injury.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

Source – PRNewswire

Zeto Announces Expert Jury for Its EEG Clinical Trial Sponsorship Program

SANTA CLARA, Calif., May 7, 2024 (Newswire.com) – Zeto, Inc., an innovative EEG brain monitoring company, is pleased to announce the distinguished members of the jury panel for its first clinical trial sponsorship program. The panel, comprising professionals from the fields of neurology and neuroscience research, will oversee the assessment and selection of clinical trials and research projects that align with Zeto’s mission to advance biomedical research and enhance patient care through innovative EEG applications.

Jury Panel Members:

Robert Fisher, MD, PhD – Dr. Fisher is the Director of the Stanford Epilepsy Center and is Zeto’s Chief Medical Advisor. He received research awards from the Klingenstein Foundation, EF, CURE and NIH. He has been named ‘Best Doctors in America’ since 1996 and received the Ambassador Award from the International League Against Epilepsy, the 2005 AES Service Award and the 2006 Annual Clinical Research Award. He is also the Past President of the American Epilepsy Society. His extensive experience and leadership in epilepsy research are invaluable to guiding the future of EEG technologies.

Michael Weisend, PhD – Dr. Weisend brings a multidisciplinary approach to the panel with his background in cognitive neuroscience, device development, and neuroimaging techniques. His work in academia, government, and industry, along with his innovative contributions to brain stimulation technologies, will provide a broad perspective on the potential applications of research topics in clinics using Zeto EEG.

Pradeep Modur, MD – Dr. Modur is a board-certified epileptologist and a Professor of Neurology at Dell Medical School at The University of Texas, Austin. Most recently, he served as the Director of the Ascension Comprehensive Epilepsy Program and as the Chair of the Ascension’s National Epilepsy Service Line. Dr. Modur is active in research and innovation, serves as a reviewer for several journals, authored multiple board review books, and is a highly sought speaker at conferences. His national recognition as an expert in epileptic disorders makes him a critical asset to the jury.

“We are thankful to all the research teams who submitted their applications. We were thrilled to receive such high-quality proposals! Now it’s time for our accomplished panel to evaluate the submissions. The assessment includes several factors such as alignment with Zeto’s vision, the potential impact on patient care, and the innovative utilization of EEG,” says Florian Strelzyk, Chief Sales Officer at Zeto.

Zeto announced at the 2023 Society for Neuroscience Convention in Washington D.C. that it invites interested research teams to submit proposal pitches by April 15, 2024, and the company would sponsor up to three clinical trials using the Zeto EEG system.

Important Dates:

Selection Completion: The rigorous selection process will commence in May and be completed by June 1st, 2024.

Public Announcement: The selected clinical research projects will be publicly announced no later than June 10th, 2024, on Zeto’s official website and social media channels.

Zeto is committed to fostering advancements in EEG technology and clinical research. Our high-caliber jury panel underscores our dedication to supporting meaningful and impactful scientific studies that can significantly improve patient outcomes.

About Zeto, Inc.

Zeto, Inc., is an award-winning, privately held medical technology company located in Santa Clara, CA, focused on transforming the way electroencephalography is done in clinical and research settings. Zeto’s revolutionary FDA-cleared EEG platform brings the traditional EEG procedure to the 21st century by offering the WR19, a zero-prep, wireless, easy-to-wear headset with active, dry electrodes that can be positioned as per the 10-20 system. The company plans to leverage its platform technology to improve access and quality to medical EEG testing and to enable and improve adjacent biomedical research and clinical trials.

To learn more about Zeto’s products, please visit https://zeto-inc.com or email us at research@zetoinc.com.

Source – Newswire

Zeto Successfully Completes SOC 2 Type II Audit for Its Cloud Platform, Demonstrating Commitment to Data Security

SANTA CLARA, Calif., March 18, 2024 (Newswire.com) – Zeto, Inc., a commercial-stage medical technology company transforming EEG brain monitoring in healthcare with its innovative EEG headset and advanced cloud platform, is proud to announce its renewal of SOC 2 Type II compliance. This critical milestone highlights Zeto’s commitment to the highest standards of security and compliance, in line with the stringent guidelines set forth by the American Institute of Certified Public Accountants (AICPA) for SOC for Service Organizations, also recognized as SSAE 18.

Achieving SOC 2 Type II compliance, with an unqualified opinion, serves as third-party industry validation that Zeto, Inc. provides enterprise-level security for customer data stored in its Cloud Platform. This accomplishment is a testament to Zeto’s unwavering commitment to data security and operational excellence, ensuring the highest standard of protection for customer information.

Aswin Gunasekar, Zeto’s founder and CEO said, “SOC Accreditation is more than a benchmark for Zeto; it’s a reflection of our deep commitment to security and privacy within the healthcare sector. By achieving this standard, we affirm our dedication to offering dependable and secure cloud services, tailored to meet the critical needs of hospitals and healthcare providers.”

Zeto Successfully Completes SOC 2 Type II Audit for Its Cloud Platform

An unqualified opinion in a SOC 2 Type II audit indicates that Zeto, Inc. manages data with the highest standard of security, providing peace of mind to both current and prospective customers about the company’s commitment to data protection and compliance.

About Zeto, Inc.

Zeto, Inc. is an award-winning, privately held medical technology company located in Santa Clara, CA, that is focused on transforming the way electroencephalography (EEG) is performed at hospitals and clinics. Zeto’s revolutionary FDA-cleared EEG headset and cloud platform bring the traditional EEG procedure to the 21st century. The company plans to leverage its hardware and software technology to improve noninvasive monitoring of the brain’s electrical activity and achieve better outcomes for neurological conditions such as epilepsy, sleep disorders, autism, stroke, and concussion.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

Source – Newswire

Zeto Adds New Chief Financial Officer to Accelerate Growth

SANTA CLARA, Calif., March 6, 2024 (Newswire.com) – Zeto, Inc., a commercial-stage medical technology company transforming EEG brain monitoring for healthcare with its innovative EEG headset and advanced cloud platform, today announced the appointment of Neway Redia as its new Chief Financial Officer. With a career spanning over 20 years, including 16 years at Siemens across multiple divisions and various countries, and last 4 years in leadership positions at medical technology startups, namely, Zap Surgical and Promaxo, Neway brings a wealth of experience and skill to help co-lead Zeto to its next stage of growth.

Aswin Gunasekar, Founder and CEO of Zeto, expressed his enthusiasm saying, “We are excited to welcome Neway Redia as our Chief Financial Officer, especially during a period of fast growth for Zeto. His diverse background, expertise, and strategic leadership are what our company needs at this pivotal phase of our journey. Under Neway’s guidance, we look forward to scaling our operations rapidly and creating the foundation for Zeto to be able to lead the industry. We are optimistic about achieving rapid market penetration with our popular EEG platform.”

Zeto announced the appointment of Neway Redia as its new Chief Financial Officer.

On joining Zeto, Neway shared, “I am super excited to join Zeto at such an important phase. The company’s market potential is huge, promising extensive opportunities for growth and innovation. As CFO, I aim to provide financial and strategic leadership to Zeto, as we transform EEG technology which is due for a change, and secure leadership position in the brain monitoring market.”

Neway will be based out of Zeto’s office in Santa Clara, working closely with the company’s management team and the board of directors.

About Zeto, Inc.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

Source – Newswire

Zeto Achieves HITRUST Risk-Based, 2-year Certification Demonstrating the Highest Level of Information Protection Assurance

HITRUST Risk-Based, 2-year (r2) Certification validates Zeto is committed to strong cybersecurity and protecting sensitive data.

SANTA CLARA, Calif., February 26, 2024 (Newswire.com) – Zeto, Inc., a commercial-stage medical technology company transforming EEG brain monitoring in healthcare with its innovative EEG headset and advanced cloud platform, today announced its ZCP (Zeto Cloud Platform) has earned certified status by HITRUST for information security.

HITRUST Risk-based, 2-year (r2) Certification demonstrates that the organization’s ZCP (Zeto Cloud Platform) has met demanding regulatory compliance and industry-defined requirements and is appropriately managing risk. This achievement places Zeto, Inc. in an elite group of organizations worldwide that have earned this certification. By including federal and state regulations, standards, and frameworks and incorporating a risk-based approach, the HITRUST Assurance Program helps organizations address security and data protection challenges through a comprehensive and flexible framework of prescriptive and scalable security controls.

Zeto Achieves HITRUST Risk-Based, 2-Year Certification Demonstrating the Highest Level of Information Protection Assurance

“We’re proud to affirm our commitment to exceptional data protection and information security standards by securing the distinguished HITRUST r2 Certification,” said Aswin Gunasekar, Founder and CEO at Zeto, Inc.

“HITRUST certification is globally recognized as validation that information security and privacy controls are effective and compliant with various regulations. HITRUST certification is considered the gold standard because of the comprehensiveness and applicability of the control requirements, depth of the assurance process, and level of oversight that ensures accuracy,” said Jeremy Huval, Chief Innovation Officer at HITRUST.

About Zeto, Inc.

To learn more about Zeto’s products, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

Source – Newswire

Zeto Exhibits at Neuroscience 2023 and Will Sponsor EEG Clinical Trials

SANTA CLARA, Calif., November 13, 2023 (Newswire.com)

Zeto, Inc., an innovative EEG brain monitoring company, is excited to make two significant announcements as the company continues to expand the boundaries of brain monitoring.

Zeto is proud to announce its inaugural participation at the Neuroscience 2023 conference hosted by the Society for Neuroscience. Taking place from November 11-15, 2023, at the Walter E. Washington Convention Center in Washington, D.C., this event will bring together over 30,000 scientists, researchers, and clinicians making it the largest conference in neuroscience.

“At Zeto, we’ve consistently delivered substantial value to our clinical partners in hospitals and private practices. Now, we’re excited to bring the convenience of Zeto EEG to the forefront of your clinical research journey. The Society for Neuroscience conference is a remarkable opportunity for us to connect with the global scientific community and facilitate the use of EEG for brain monitoring,” said Florian Strelzyk, PhD, Chief Sales Officer at Zeto. “Zeto understands your need for ease of use, comfort, and a refined experience with EEG technology. We believe our products will unlock a world of new opportunities, enabling EEG researchers to step out of the lab and into research environments closely aligned with their interests. We invite attendees to visit our booth #2430 in the Exhibitor Hall to discover and experience our innovative EEG solutions for clinical trials and research.”

Zeto reaffirms its commitment to increasing accessibility to brain monitoring by sponsoring up to three EEG clinical trials in 2024. These trials aim to support advanced clinical research and bring innovative applications closer to full real-world implementation.

Each sponsored clinical trial will enjoy the following benefits:

WR19 EEG System: Each sponsored clinical trial will benefit from Zeto’s EEG device, an FDA-cleared, wireless, portable, dry-electrode, full 10-20 montage EEG headset with high-quality data collection and a fast and comfortable 5-minute setup.
Cloud Access: Access to HIPAA-compliant, cyber-security cleared cloud platform for efficient data storage, remote access, EDF export, and real-time LSL data streaming.
Disposable Electrodes: Zeto will provide disposable electrodes for up to 100 EEG recordings in each clinical trial. These electrodes are designed for comfort and ease of use, enhancing the participant experience.
TTL-based Triggering for ERP Recordings: If required, the Zeto system will include an additional component for real-time TTL-based triggering for evoked potentials, along with additional stimulus presentation software and hardware.
Training and Support: To ensure a smooth and successful implementation of Zeto’s EEG solutions, the company provides training and ongoing support to clinical trial teams.

To participate in this opportunity, interested research teams are invited to submit a 2-page proposal or project pitch by March 31st, 2024. Further details and submission guidelines can be found on the Zeto Clinical Trials Sponsorship webpage.

Zeto is dedicated to enhancing the accessibility of brain monitoring. For more information about Zeto, please visit Zeto’s website.

Source – Newswire

Exploring Zeto’s Dry EEG Headset: Advantages for Medical Research

Zeto has been providing value to clinical customers in hospitals and private practices for some time now. However, we have recently extended our offerings to CROs and cutting-edge researchers in the field of medical research. A. Mark Mento, director of enterprise sales here at Zeto, discusses the advantages of Zeto’s dry EEG headset for researchers, highlighting its ease of use, comfort, and potential to bring EEG out of the lab and into the medical research environment.

Zeto recently introduced new features for clinical research applications. Where does Zeto fit into the research world?

Zeto offers a unique solution within the research world as our EEG for research represents a combination of technology from both the medical device and academic research space.

Our EEG for clinical research is particularly useful for studies that involve participants from clinical populations, or are conducted in a clinical environment. The Zeto system is fully FDA-cleared, ensuring compliance with rigorous medical standards for data quality and privacy, ensuring an easier Institutional Review Board (IRB) process.

Because the Zeto system conforms to medical standards regarding electrode position and data quality, it is compatible with large clinical EEG datasets. Researchers utilizing these databases to train biomarkers and machine learning algorithms will be able to apply their work directly to Zeto data.

The Zeto system achieves medical conformity while allowing a much faster and more comfortable setup without requiring gel, scalp prep. The system allows for real-time data streaming via LSL, remote data access via API, and high-fidelity triggering for visual evoked potential tests.

What specific advantages does Zeto offer to researchers over conventional wet electrode systems in terms of usability?

Gel-based systems take a while to set up and are uncomfortable for participants. They usually require some degree of scalp preparation (scratching the electrode site to remove dead skin and other material) and they leave gel in the hair that must be showered out.

When gel-based EEGs are used for medical research, it is difficult for a participant to leave a test and return to class or work. Additionally, medical-style gel EEG systems require a qualified technologist to measure the head and to apply electrodes in the correct place.

The Zeto EEG system provides two advantages over this process.

First, the system uses disposable electrodes with a dry soft-tip coating. This allows for proper electrical conductivity with the scalp without requiring prep or gel.
Second, the headset is mechanically adjustable to the head size of the participant, ensuring that the electrodes are in the correct 10-20 positions. This feature allows individuals without knowledge of electrode replacement and EEG to set up the system accurately with minimal training.

Together, these features allow the system to be set up very quickly on most participants, typically within 5 minutes. It is also much more comfortable for the participant and when the test is over the system is removed instantly with no residual gel left behind.

What research-specific features does the system include?

We offer a range of specific features on our eeg for medical research that cater to the unique and specific needs of researchers.

For example, the system includes a comprehensive API for both real-time local data streaming, and cloud-based data access. Zeto EEG data can be integrated directly into experiments, utilizing the full range of data access capabilities.

The Zeto platform can also accept epoch trigger inputs for event-related potentials (ERPs) and other timing-sensitive experiments, expanding the possibilities for research applications.

Overall, Zeto provides cutting edge features for both clinical and research applications, offering researchers enhanced usability, accurate data acquisition, and the flexibility to conduct various experiments.

Can you provide examples of potential future applications of EEG technology in research, and how Zeto’s system might contribute to advancements in these areas?

EEG technology is expanding in medical and mental health applications beyond the traditional domains of epilepsy and stroke.

Researchers are increasingly exploring the use of machine learning techniques applied to EEG data for potential screening, diagnostics and interventions. Information from EEGs used for research could help diagnose certain conditions, or to evaluate and quantify the effects and success of certain treatment paradigms.

Zeto’s EEG system is well-positioned to contribute to these advancements in several ways.

First, the Zeto EEG headset has direct medical applicability. Since data from the headset is functionally identical to traditional medical EEG in terms of data quality and electrode position, any pioneering research conducted using Zeto’s system can directly translate to the clinical market.
Second, Zeto’s system provides a practical and comfortable solution for running participants in a clinical environment. It offers ease of setup and enhanced practicality, streamlining the process for researchers and facilitating data collection in clinical settings.

Can you share some information about Zeto’s current research customers and the successful projects?

The Zeto EEG for research is new in the research space, specifically. But we already have a diverse range of research customers.

Our products have been used in clinical trials on three continents (and counting). Additionally, we have established collaborations and installed equipment in numerous academic research labs in universities and teaching hospitals.

These partnerships highlight the growing adoption of Zeto’s system within the research community, leading to successful projects across various domains.

What types of support or training Zeto provides to researchers who are new to working with EEG technology?

For Zeto systems purchased in North America, we provide on-site training. Our dedicated customer success team is readily available to address any inquiries or support-related questions promptly.

Zeto Voted Best Current Neurology Solution in 2023 by MedTech Breakthrough Awards

Prestigious International Annual Awards Program Recognizes Standout Digital Health & Medical Technology Products and Companies

SANTA CLARA, Calif., – May 22, 2023 – Zeto, Inc , a commercial-stage medical technology company transforming EEG brain monitoring for health care, today announced that it is the recipient of the “ Best New Technology Solution for Neurology ” award in the 7th annual Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies, and products in the global health and medical technology market.

Zeto makes it possible for any healthcare facility to offer a convenient, turnkey EEG solution to their patients. The company provides the first and only FDA-cleared, wireless, dry EEG headset that can be put on by any medical staff within five minutes.

The Zeto Cloud provides high-performance, real-time viewing, analysis, and reporting. Live video and data can be interpreted seamlessly via the cloud, and is further enabled by AI-based, FDA-cleared seizure detection. Zeto also offers optional continuous monitoring by certified EEG technologists, and interpretation services by board-certified neurologists.

EEG device innovation, important among current neurology solutions, highlights include active electrode technology, 10-20 positioning, soft, flexible electrodes, comfort for patients, advanced noise shielding and noise cancellation, and clinical-grade signal quality. Built to feel like a bike helmet, the device offers easy head size adjustment via adjustable dials.

“The massive unmet need for brain monitoring extends beyond neurology departments to ICUs, EDs, remote monitoring, telehealth, and physician offices. At Zeto, we want to eliminate any negative experience with a product that is both convenient for the operator and comfortable for the patient,” said Aswin Gunasekar, CEO of Zeto, Inc. “Receiving the ‘Best New Technology Solution for Neurology’ award from MedTech Breakthrough is a testament to the value our product is delivering.”

The mission of the MedTech Breakthrough Awards is to honor excellence and recognize the innovation, hard work, and success in a range of health and medical technology categories, including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data and many more. This year’s program attracted more than 4,000 nominations from over 17 different countries throughout the world.

“The portable nature of this EEG headset from Zeto has amazing potential for patients and practitioners, especially as it offers similar signal quality to traditional devices,” said James Johnson, managing director, MedTech Breakthrough.

“EEG is an important diagnostic technique for several neurological issues. However, the biggest limiting factor is that conventional EEG needs a trained operator to administer the test, and if a facility doesn’t have a neurologist on call, they are unable to read the EEGs. Congratulations to Zeto for transforming the way we perform EEGs, with tangible and real results.”

Zeto is serving over 200 healthcare facilities with more than 45,000 clinical EEGs performed.

About Zeto, Inc.

To learn more about Zeto’s neurology solutions including remote EEG monitoring, please visit: https://zeto-inc.com or email us at info@zetoinc.com.

Zeto Introduces New Features for Clinical Research Applications to Address the Growing Need for Rapid Brain Monitoring in Health Sciences

SANTA CLARA, Calif., – May 18, 2023

Zeto, Inc., an innovative EEG brain monitoring company, announced its participation in the upcoming Vision Sciences Society (VSS) annual meeting in St. Pete Beach, Florida, from May 19th to 24th.

The Vision Sciences Society (VSS) Annual Meeting is a premier gathering that covers the broad scope of vision science. The meeting brings together experts from various disciplines, including visual psychophysics, visual neuroscience, computational vision, and visual cognition. As part of this event, Zeto, Inc. will showcase its latest product features tailored for EEG in clinical research applications.

Originally developed for the rapid acquisition of clinical EEGs in hospitals and clinical practices, Zeto is responding to an increasing number of requests from researchers and clinical research organizations (CROs) who share a common need for high-quality EEGs recorded more efficiently compared to traditional technologies.

The research features introduced by Zeto include the ability to record timing-precise event- related potentials (ERPs) through their unified cloud platform. Users can now benefit from the ease and security of Zeto’s cloud interface yet maintaining sub-millisecond precision on input and output event markers which are crucial for high-end ERP data acquisition. This cloud platform is particularly relevant for CROs and large-scale multi-site research projects, providing a central place for data access and management.

With advanced API features, state-of-the-art encryption and user management, researchers can conveniently interact with EEG and synchronized video data using commonly available scripting languages such as Python®, MATLAB®, or most other programming languages. This significantly speeds up the ability to process large multi-site datasets and fosters collaboration and synergies among multi-center stakeholders.

“Zeto has been providing tremendous value for our clinical customers in hospitals and private practices, but we are particularly excited to now offer the convenience of Zeto EEG to CROs and cutting-edge researchers,” says Florian Strelzyk, Chief Sales Officer at Zeto. “The ease of use, comfort, and refined feel of our products will open up a wide range of new opportunities to bring EEG out of the lab and into research environments that are closely related to the topics they study. Imagine the possibilities ahead with a platform that is quick to apply and easy to work with. Successful research frequently relies on large teams extracting clinical findings efficiently and Zeto can provide this multi-user experience like no other tool currently available.”

About Zeto

Zeto, Inc., is an award-winning, privately held medical technology company located in Santa Clara, CA focused on transforming the way electroencephalography is done in clinical and research settings. Zeto’s revolutionary FDA-cleared EEG platform brings the traditional EEG procedure to the 21st century by offering the WR19, a zero-prep, wireless, easy-to-wear headset with active, dry electrodes that can be positioned as per the 10-20 system.
The Zeto headset is backed by a cloud data and software platform, a real-time LSL-based API, and a TTL-based trigger device for ERP studies.
The company plans to leverage its platform technology to improve access and quality to medical EEG testing and to enable and improve adjacent biomedical research and clinical trials.

To learn more about Zeto’s products, including the remote EEG monitoring, please visit: https://zeto-inc.com or email us at research@zetoinc.com

Source – Newswire

Greenwood Leflore Hospital Elevates Patient Care with Advanced EEG Solutions

Greenwood, Mississippi, February 15, 2023 –

Greenwood Leflore Hospital in Greenwood, MS has recently upgraded its EEG capabilities with the implementation of a modern solution. The hospital, which has always prioritized offering in-house EEG tests for its patients, has adopted a technology that allows for a faster and more efficient EEG experience.

Patients can now benefit from a shorter setup time and a more convenient testing process, without the need for skin prep or gel. The new technology has received positive feedback from patients, who appreciate the faster scheduling, the lack of need for post-test hair washing and simplified testing process.

“The new EEG solution has been a valuable addition to our hospital,” says Steven Robinson, Director of Cardiopulmonary Care at Greenwood Leflore Hospital. “It offers a more efficient and patient-friendly approach to EEGs, while also providing high-quality results.”

“We are proud to support the improvements to patient care at Greenwood Leflore Hospital through the implementation of our EEG solution,” says Florian Strelzyk, Chief Sales Officer at Zeto, Inc. “Providing on-site testing is a crucial aspect of quality patient care and we are pleased to be able to contribute to this.”

The hospital’s ability to perform routine and urgent EEGs at a moment’s notice has also been improved, allowing for better patient care and a more streamlined experience. The EEG headset simplifies the testing process for both patients and healthcare providers.

In conclusion, Greenwood Leflore Hospital’s upgrade to its EEG capabilities has made EEG testing a quick and comfortable experience for patients, further enhancing the hospital’s commitment to providing top-notch care.

About Greenwood Leflore hospital:
Greenwood Leflore Hospital is a publicly-owned healthcare organization. The Hospital was established in 1906 by the King’s Daughters’ Society with the help of the City of Greenwood and Leflore County.
Website
http://www.glh.org

Source:
https://www.einpresswire.com/article/617160083/greenwood-leflore-hospital-elevates-patient-care-with-advanced-eeg-solutions